Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)
Background: Psoriasis is associated with a variety of psychological difficulties, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation. Objectives: The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the effecti...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | Journal of Dermatology and Dermatologic Surgery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352241014000085 |
| _version_ | 1818149296377167872 |
|---|---|
| author | Ayman Elgendi Hanan Nada Al Sadat Mosbeh Mona Maatouk Majdy Abulghany Wayne Gulliver |
| author_facet | Ayman Elgendi Hanan Nada Al Sadat Mosbeh Mona Maatouk Majdy Abulghany Wayne Gulliver |
| author_sort | Ayman Elgendi |
| collection | DOAJ |
| description | Background: Psoriasis is associated with a variety of psychological difficulties, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation.
Objectives: The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the effectiveness of adalimumab treatment on the depression symptoms associated with psoriasis and to explore the association between improvement in depression symptoms and improvement in Psoriasis Area and Severity Index.
Methods: The effects of adalimumab (40 mg every other week) on ZDS score and PASI at week 24 were assessed. Relationships between ZDS and PASI were assessed. Changes in ZDS score were compared for patients with and without a 75% or greater reduction in baseline PASI score. An improvement of 6 points or more in the Zung depression scale was considered a clinically meaningful improvement.
Results: Forty five Patients with moderate to severe psoriasis were assessed for depression symptoms at baseline and week 24 using the Zung Self-rating Depression Scale (ZDS). At month 6 after starting adalimumab, 80% of enrolled patients achieved 75% improvement in their PASI score (PASI75) at month 6 of adalimumab therapy and 97.8% achieved a meaningful improvement of Zung depression score (more than 6 points decline in the Zung depression score). Age at time of assessment significantly predicted depression (p = 0∗030), with the younger age predicting a higher depression score (standard co-efficient -.451). Achieving PASI 75 could significantly predict improvement in depression (p = 0.002, standard coefficient-.746).
Conclusion: Adalimumab may be associated with relief symptoms of depression in patients with moderate to severe psoriasis. Reductions in depression symptoms were significantly correlated with reductions in psoriasis severity. |
| first_indexed | 2024-12-11T13:04:47Z |
| format | Article |
| id | doaj.art-a098432b9c8f4d489da59788a3ef22d6 |
| institution | Directory Open Access Journal |
| issn | 2352-2410 |
| language | English |
| last_indexed | 2024-12-11T13:04:47Z |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Dermatology and Dermatologic Surgery |
| spelling | doaj.art-a098432b9c8f4d489da59788a3ef22d62022-12-22T01:06:21ZengWolters Kluwer Medknow PublicationsJournal of Dermatology and Dermatologic Surgery2352-24102015-01-01191152010.1016/j.jdds.2014.03.005Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)Ayman Elgendi0Hanan Nada1Al Sadat Mosbeh2Mona Maatouk3Majdy Abulghany4Wayne Gulliver5Dermatology Department, Saudi Arabian Airlines Medical Services, Jeddah, Saudi ArabiaDermatology Department, Dr. Soliaman Fakeeh Hospital, Jeddah, Saudi ArabiaDermatology Department, Faculty of Medicine, Al Azhar University, EgyptConsultant Dermatology, King Fahd General Hospital, Jeddah, Saudi ArabiaConsultant Dermatology, Head of Department of Dermatology, King Fahd Armed Forces Hospital,Jeddah, Saudi ArabiaFaculty of Medicine, Memorial University of Newfoundland, CanadaBackground: Psoriasis is associated with a variety of psychological difficulties, including poor self-esteem, sexual dysfunction, anxiety, depression, and suicidal ideation. Objectives: The aim of this study was to obtain further data on the extent of depression among psoriatic patients, the effectiveness of adalimumab treatment on the depression symptoms associated with psoriasis and to explore the association between improvement in depression symptoms and improvement in Psoriasis Area and Severity Index. Methods: The effects of adalimumab (40 mg every other week) on ZDS score and PASI at week 24 were assessed. Relationships between ZDS and PASI were assessed. Changes in ZDS score were compared for patients with and without a 75% or greater reduction in baseline PASI score. An improvement of 6 points or more in the Zung depression scale was considered a clinically meaningful improvement. Results: Forty five Patients with moderate to severe psoriasis were assessed for depression symptoms at baseline and week 24 using the Zung Self-rating Depression Scale (ZDS). At month 6 after starting adalimumab, 80% of enrolled patients achieved 75% improvement in their PASI score (PASI75) at month 6 of adalimumab therapy and 97.8% achieved a meaningful improvement of Zung depression score (more than 6 points decline in the Zung depression score). Age at time of assessment significantly predicted depression (p = 0∗030), with the younger age predicting a higher depression score (standard co-efficient -.451). Achieving PASI 75 could significantly predict improvement in depression (p = 0.002, standard coefficient-.746). Conclusion: Adalimumab may be associated with relief symptoms of depression in patients with moderate to severe psoriasis. Reductions in depression symptoms were significantly correlated with reductions in psoriasis severity.http://www.sciencedirect.com/science/article/pii/S2352241014000085PsoriasisAdalimumabDepression |
| spellingShingle | Ayman Elgendi Hanan Nada Al Sadat Mosbeh Mona Maatouk Majdy Abulghany Wayne Gulliver Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) Journal of Dermatology and Dermatologic Surgery Psoriasis Adalimumab Depression |
| title | Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) |
| title_full | Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) |
| title_fullStr | Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) |
| title_full_unstemmed | Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) |
| title_short | Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps) |
| title_sort | depression over psoriasis assessment of associated relief by addition of adalimumab for the treatment of psoriasis observational study dorado ps |
| topic | Psoriasis Adalimumab Depression |
| url | http://www.sciencedirect.com/science/article/pii/S2352241014000085 |
| work_keys_str_mv | AT aymanelgendi depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops AT hanannada depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops AT alsadatmosbeh depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops AT monamaatouk depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops AT majdyabulghany depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops AT waynegulliver depressionoverpsoriasisassessmentofassociatedreliefbyadditionofadalimumabforthetreatmentofpsoriasisobservationalstudydoradops |